AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$NCNA

NuCana plc

Price · $NCNAvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $NCNA in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $NCNA in the last 30 days.

Top stories · $NCNAMore →
MAY 17·AD HOC NEWSLow

NuCana plc stock (GB00BD8P0H86): liquidation plan and delisting reshape outlook

NuCana plc is moving towards a complete liquidation and dissolution after failing to secure a strategic deal, impacting its previous focus on oncology drug development. The company plans to distribute remaining cash to shareholders and delist from Nasdaq, shifting investor focus from growth potential to residual value recovery. This process highlights risks for US investors in early-stage biotech, as NuCana's case exemplifies the challenges of capital-intensive drug development and the importance of market access and clinical data.

APR 9·Traders Union

-6.83% for NuCana stock as tight trading range restricts moves

NuCana stock (NCNA) dropped 6.83% to $1.91, exhibiting short-term strength above its 20-day SMA but remaining below its 50-day and 200-day SMAs, indicating persistent medium and long-term technical pressure. Mixed momentum indicators and strong selling biases suggest that while buyers are active, a sustained uptrend is unlikely. Analysts expect NCNA to trade sideways between $1.85 and $2.10 in the near term, with a higher probability of downside movement.

MAR 19·TipRanks

NuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029

NuCana reported its 2025 financial results, emphasizing promising clinical progress with its oncology pipeline, particularly NUC-7738, which demonstrated encouraging activity in PD-1 resistant melanoma. The company concluded 2025 with £24.3 million in cash and cash equivalents, projecting a cash runway extending into 2029 to fund its operations. Despite a wider net loss in 2025 due to non-cash expenses, NuCana is advancing NUC-7738 towards Phase 2 completion and regulatory milestones, while refining its development strategy for NUC-3373.

News on $NCNA